Teva Pharmaceutical has agreed to pay $1.1 million to settle a class-action lawsuit with consumers who accused a subsidiary of the generic drugmaker of participating in a “pay-for-delay” arrangement with Takeda Pharmaceutical’s Shire subsidiary.

The 2016 lawsuit alleged that Actavis, which Teva acquired that year, had a pay-for-delay deal with Shire that delayed the launch of a generic of Shire’s attention deficit hyperactivity disorder (ADHD) drug Intuniv (guanfacine).

The proposed settlement, which must first be approved by the U.S. District Court for the District of Massachusetts, will go to the consumers who argued the anticompetitive practice deprived them of a lower cost alternative to Intuniv.